米非司酮保守性治疗围绝经期子宫肌瘤的疗效及影响因素

[目的]探讨米非司酮保守性治疗围绝经期子宫肌瘤的疗效及影响因素.[方法]收集2010年12月至2016年6月在本院接受治疗的子宫肌瘤患者40例,采用米非司酮治疗,比较治疗前后子宫肌瘤的体积变化,分析米非司酮治疗效果的影响因素.[结果]治疗后子宫肌瘤体积明显缩小(P<0.05);子宫肌瘤体积大于3 cm、ER受体阴性、子宫肌瘤病程>6个月及肌瘤位置位于浆膜下的患者,米非司酮治疗效果较差(P<0.05),而不同年龄或子宫肌瘤病理类型中,米非司酮治疗效果无差异(P>0.05);多因素Logistic回归分析显示,ER受体、肌瘤大小、病程是影响因素米非司酮治疗效果的独立风险因素(P<0.05).[结论]米非司酮保守性治疗子宫肌瘤疗效显著,而ER受体、肌瘤大小及病程是影响到米非司酮治疗效果的主要因素.

Clinical Effect and Influencing Factors of Mifepristone in the Conservative Treatment of Peri Menopausal Uterine Fibroids

[Objective]To investigate the clinical effect of mifepristone in the treatment of uterine fibroids and its influencing factors.[Methods]Forty patients with myoma of uterus treated in our hospital from December 2010 to June 2016 were selected;Mifepristone was used to compare the volume change of hysteromyoma before and after treatment,and the factors influencing the effect of mifepristone treatment were analyzed.[Results]The volume of myoma of uterus decreased significantly after treatment (P<0.05);The effect of mifepristone was poor in patients with myoma of uterus larger than 3 cm,ER receptor negative,uterine fibroids >6 months and the fibroids located under the serosa(P<0.05).[Conclusion]Mifepristone is effective in the treatment of uterine fibroids;ER receptor,myoma size and course of disease are the main factors that influence the effect of mifepristone treatment.